BioMarin regulatory update
BioMarin said that EMA's CHMP recommended approval of an expansion to its biologics manufacturing facility in Novato, Calif. The company expects a final decision from EMA in 1Q12 on the expansion, which BioMarin expects to double the site's capabilities and support up to $1 billion in revenue for its enzyme replacement...
Read the full 235 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Week In Review
Article Purchase
$30 USD
